What type of study is this?

This is a Pre-Registered Trial study.

What question did this study set out to answer?

To evaluate the effects of adavosertib combined with chemotherapy agents on non-small-cell lung cancer.

November 10, 2025Targeted OncologyOpen Access

View Full Paper

Ask AI

Bookmark

To evaluate the effects of adavosertib combined with chemotherapy agents on non-small-cell lung cancer.
Conducted two Phase II clinical trials.
Administered adavosertib in combination with docetaxel or carboplatin plus pemetrexed.
Trials registered as NCT02087241 and NCT02087176.
Investigated the safety and efficacy of adavosertib with docetaxel or carboplatin and pemetrexed.
Results may indicate improved outcomes for patients with non-small-cell lung cancer.

We only have this paper's title and publication details.

Phase II trials assessed adavosertib with carboplatin or pemetrexed in non-small-cell lung cancer, implying potential treatment benefits.

ClinicalTrials.gov, NCT02087241 and NCT02087176.

No takes yet. Share an insight, caveat, or question.

Johnson et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Phase II trials assessed adavosertib with carboplatin or pemetrexed in non-small-cell lung cancer, implying potential treatment benefits.

ClinicalTrials.gov, NCT02087241 and NCT02087176.